

Company Overview

Lantern Pharma is a clinical stage biotechnology company focused on innovating the cancer drug development process by using advanced genomics, machine learning, and artificial intelligence ("A.I."). Our A.I. platform, known as RADR®, currently includes more than 60 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then to identify the cancer patients that we believe may benefit most from our compounds. RADR® is also used by Lantern and its collaborators to 1) develop and position new drugs and 2) to rescue and reposition drug candidates that others have tried, but failed, to develop.

Lantern's current portfolio consists of four drug candidates and an ADC program across eleven disclosed tumor targets, including two Phase 2 programs and several additional Phase 1 clinical trials anticipated for 2023. Lantern seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to assist with its objective of delivering cancer therapies to patients as quickly and cost-effectively as possible. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development.

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Mar 18 2024, 4:02 PM EDT

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Mar 15 2024, 8:00 AM EDT

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Mar 11 2024, 7:30 AM EDT

Stock Overview

Symbol	LTRN
Exchange	Nasdaq
Market Cap	61.98m
Last Price	\$5.77
52-Week Range	\$2.38 - \$11.99

04/18/2024 04:00 PM EDT

Executive Team

Panna Sharma

Chief Executive Officer, President and Director

David R. Margrave

Chief Financial Officer and Secretary

Kishor G. Bhatia, Ph.D.

Chief Scientific Officer

Lantern Pharma Inc.

1920 McKinney Avenue
7th Floor
Dallas, TX 75201

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.